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Abstract The orexigenic peptide ghrelin plays a promi-
nent role in the regulation of energy balance and in the
mediation of reward processes and reinforcement for
addictive drugs, such as nicotine. Nicotine is the principal
psychoactive component in tobacco, which is responsible
for addiction and relapse of smokers. Ghrelin and nicotine
activates the mesolimbicocortical dopaminergic pathways
via growth hormone secretagogue receptors (GHS-R1A)
and nicotinic acetylcholine receptors (nAchR), respectively,
resulting in the release of dopamine in the nucleus accum-
bens, the amygdala and the prefrontal cortex. In the present
study an in vitro superfusion of rat amygdalar slices was
performed in order to investigate the direct action of ghrelin
and nicotine on the amygdalar dopamine release. Ghrelin
increased significantly the dopamine release from the rat
amygdala following electrical stimulation. This effect was
inhibited by both the selective GHS-R1A antagonist GHRP-
6 and the selective nAchR antagonist mecamylamine. Under
the same conditions, nicotine also increased significantly the
dopamine release from the rat amygdala. This effect was
antagonized by mecamylamine, but not by GHRP-6.
Co-administration of ghrelin and nicotine induced a similar
increase of amygdalar dopamine release. This stimulatory
effect was partially reversed by both GHRP-6 and meca-
mylamine. The present results demonstrate that both ghrelin
and nicotine stimulates directly the dopamine release in the
amygdala, an important dopaminergic target area of the
mesolimbicocortical pathway.
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Introduction
Ghrelin is a 28-amino acid orexigenic peptide, which was
originally isolated from the rat stomach [1, 2]. It acts on the
growth hormone secretagogue receptor (GHS-R), which
has two isoforms (GHS-R1A and GHS-R1B) [3]. GHS-
R1A, apart from GH release, was proved to mediate food
intake and energy balance, reward, addiction, memory,
arousal and neuroprotection [4]. GHS-R1B is thought to
regulate/inhibit the actions of GHS-R1A [5].
Nicotine is the principal psychoactive component in
tobacco, which is responsible for addiction and relapse of
smokers [6]. Nicotine exerts its effects on the central ner-
vous system by the activation of nicotinic acetylcholine
receptors (nAchRs) [7]. The dopaminergic neurons of the
mesencephalon express a variety of nAchR subtypes
which, when activated by nicotine, promote a sustained
increase in dopamine release in the target areas. This
process was found essential to the development of nicotine
addiction [8] and could be inhibited by the non-selective,
competitive nAchR antagonist mecamylamine [9].
Nicotine, infused directly into the dopaminergic target
areas, elevates dopamine release from the nerve terminals
and this effect is blocked by mecamylamine [9]. The
principal dopaminergic pathways arise from the medioba-
sal hypothalamus (tuberoinfundibular pathway), ventral
tegmental area (VTA, mesolimbicocortical pathways) and
the substantia nigra (mesostriatal pathway) [10]. The VTA
gives rise to the mesolimbicocortical pathway and inner-
vates the nucleus accumbens (NAcc), the amygdala,
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especially the central (CeA) and the basolateral (BLA)
amygdalar nuclei and the prefrontal cortex [11–13].
Previous articles suggested that ghrelin activates the
cholinergic-dopaminergic reward link [14–16]. This
reward link encompasses the cholinergic afferent projec-
tion from the laterodorsal tegmental area (LDTg) to the
VTA and the dopaminergic mesolimbic pathway projecting
from the VTA to the NAcc [17]. Several lines of evidence
support that this link mediates the reward and reinforce-
ment for both natural and artificial rewards and addictive
drugs, such as nicotine [18–20]. Ghrelin presumably, via
activation of this reward link, increases the incentive value
of motivated behaviors such as reward seeking [16].
Recent articles demonstrated that ghrelin has a promi-
nent impact on the amygdala, an important dopaminergic
target area of the mesolimbicocortical pathway [21–23].
The role of amygdala in reward mechanisms and drug
addiction is underlined by the anatomical concept of the
extended amygdala circuit, which consists of the central
nucleus of amygdala (CeA), the bed nucleus of stria ter-
minalis (BNST) and the shell of NAcc [12]. The nuclei of
extended amygdala circuit have similar cell morphology,
immunohistochemistry, and common afferent (VTA and
limbic areas, such as the hippocampus, the basolateral
amygdala (BLA), the midbrain, and the lateral hypothala-
mus) and efferent projections (VTA, the ventral pallidum,
the brainstem and the lateral hypothalamus) [24] modu-
lating drug reward and addiction to drugs, such as nicotine
[25, 26].
Recently published studies have focused upon the action
of ghrelin on the accumbal dopamine release and its
interaction with addictive drugs. In these studies, ghrelin
was administered peripherally, intracerebroventricularly or
locally, into the LDTg or the VTA [14–16]. However, these
studies provided no evidence about the direct effect of
ghrelin on the dopaminergic target areas of the VTA, such
as the amygdala. Therefore, in this study an in vitro
superfusion of rat amygdalar slices was performed in order
to investigate the action of ghrelin and nicotine on the
amygdalar dopamine release. In the present experiments
ghrelin and nicotine were applied directly into the amyg-
dala, in single or in co-administration.
Materials and Methods
Animals Used
Male Wistar rats weighing 150–250 g were used. During
the experiments every effort was made to limit the number
of animals used, and to minimize animal suffering. The
animals were kept according to the rules of the Ethical
Committee for the Protection of Animals in Research
(University of Szeged, Hungary).
Chemicals Used
Rat amygdalar slices were prepared, incubated and super-
fused with Krebs solution (composition: 113 mM NaCl,
4.7 mM KCl, 1.2 mM MgSO4, 25 mM NaHCO3, 11.5 mM
glucose, 1.2 mM KH2PO4, 2.5 mM CaCl2, pH 7.4; Reanal,
Hungary). [3H]dopamine ([3H]DA) (specific activity: 14
Ci/mmol) was purchased from PerkinElmer Inc., USA. The
slices were pretreated with 100 lM mecamylamine, a non-
selective nAch receptor antagonist (Sigma-Aldrich Inc.,
USA) or with 1 lM [D-Lys3]-growth hormone releasing
peptide-6 (GHRP-6), a selective GHS-R1A antagonist
(Sigma-Aldrich Inc., USA), then treated with 1 lM ghrelin
(Bachem Inc., Switzerland) or 100 lM nicotine (Bachem
Inc., Switzerland) or both.
Experimental Procedures
An in vitro superfusion method [27, 28] was utilized to
determine the effects of ghrelin and nicotine on amygdalar
dopamine release. The rats were decapitated and their
brains were rapidly removed. The amygdalae were isolated
and dissected in a Petri dish filled with ice-cold Krebs
solution. The amygdalae were prepared according to the
Stereotaxic atlas of the rat brain [29]. The left and right
poles of the temporal lobes were dissected in the frontal
plane at the anterior (approximately 1.5 mm rostrally from
the bregma) and the posterior (approximately 2 mm cau-
dally from the bregma) borders of the amygdalae. The
amygdalae were then decapsulated from the surrounding
white matter with the help of a stereomicroscope. External
skull reference values were extrapolated to brain coordi-
nates using the limits of the hemispheres such as, the
anterior poles and the fissure between the cerebrum and the
cerebellum. In the sagittal plain, the bregma is approxi-
mately in 4 mm distance from the anterior pole, therefore
the reference coordinates can be calculated with subtract-
ing 4 mm from the bregma value according to the abscissa.
The extracted amygdalae were cut with a McIlwain tissue
chopper and slices of 300 lM were produced. The slices
were incubated for 30 min in 8 ml of Krebs solution,
submerged in a water bath at 37 C and gassed through a
single use needle with a mixture of 5 % CO2 and 95 % O2.
During the incubation, the medium was supplemented with
0.15 lmol [3H]DA. The total amount of radioactivity used
for labeling tissue dopamine stores was 0.042 lCi/ml and
the tissue content of radioactivity was 0.386 lCi/ml. Two
tritiated slices were transferred to each of the four cylin-
drical perspex chambers of the superfusion system (Expe-
rimetria Ltd., Hungary). A multichannel peristaltic pump
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(Gilson Minipuls 2) was used to maintain a constant
superfusion rate of 300 ll/min. The superfusion was per-
formed for 30 min to allow tissue equilibrium, then the
samples were collected for 32 min in Eppendorf tubes by a
multichannel fraction collector (Gilson FC 203B). 20 min
prior to sample collecting, the slices were pretreated with
100 lM mecamylamine or with 1 lM GHRP-6. 10 min
prior to sample collecting, the slices were treated with
1 lM ghrelin, 100 lM nicotine or combined. Gold elec-
trodes were attached to both halves of the superfusion
chambers and connected to an ST-02 electrical stimulator
(Experimetria Ltd., Hungary). Two minutes after the
sample collection had started, electrical stimulation con-
sisting of square-wave impulses (total duration: 2 min,
voltage: 100 V, pulse length: 5 ms, frequency: 10 Hz)
were delivered to each of the four chambers. The remnants
of the superfused brain slices were solubilized in 200 ml of
Krebs solution, using an ultrasonic homogenizer (Branson
Sonifier 250, Labequip Ltd., Canada). The radioactivity in
the fractions and the homogenized tissue samples was
measured with a liquid scintillation spectrometer (Tri-carb
2100TR, Packard, USA) and expressed in count per minute
(CPM) after the addition of 3 ml of scintillation fluid
(Ultima Gold, Perkin Elmer Inc., USA). 16 fractions were
collected and 200 ll were extracted from each fraction to
determine the fractional [3H]DA release. The fractional
[3H]DA release was calculated as percentage of the
radioactivity present in the collected sample relative to the
total radioactivity of the corresponding tissue. The statis-
tical analysis was performed for each fraction, but the most
significant differences have been observed at the 14 min
fractions.
Statistical Analysis
Statistical analysis of the results was performed by repe-
ated measure analysis of variance (RMANOVA, Statistica
v5.0, StatSoft Inc.) followed by Tukey’s post hoc com-
parison test. Only the mean percentages were plotted and
the standard error of the mean (SEM) is given in the figure
captions. The differences between groups were examined
by Tukey’s post hoc comparison test, and a probability
level of 0.05 or less was accepted as indicating a statisti-
cally significant difference.
Results
Ghrelin increased significantly the fractional [3H]DA release
from rat amygdala slices following electrical stimulation
[F14min(1, 10) = 82.4272, p \ 0.05 for ghrelin versus con-
trol]. This effect was completely reversed by GHRP-6
[F14min(1, 10) = 62.1864, p \ 0.05 for ghrelin ? GHRP-6
versus ghrelin], and it was partially reversed by mecamyl-
amine [F14min(1, 10) = 16.0746, p \ 0.05 for ghre-
lin ? mecamylamine versus ghrelin] (Fig. 1).
Nicotine also increased significantly the fractional
[3H]DA release from rat amygdala slices following electrical
stimulation [F14min(1, 10) = 40.5000, p \ 0.05 for nicotine
versus control]. This effect was inhibited significantly by
mecamylamine [F14min(1, 10) = 28.5480, p \ 0.05 for nic-
otine ? mecamylamine versus nicotine], but it was not
influenced considerably by GHRP-6 [F14min(1, 10) = 1.1732,
p = 0.3041 for nicotine ? GHRP-6 versus nicotine] (Fig. 2).
Ghrelin combined with nicotine elevated significantly
the fractional [3H]DA release from rat amygdala slices
following electrical stimulation [F14min(1, 10) = 54.6615,
p \ 0.05 for ghrelin ? nicotine versus control]. Co-
administration of ghrelin and nicotine produced a similar
increase of amygdalar dopamine to that induced by single
administration of ghrelin or nicotine. The elevation of the
amygdalar dopamine release observed in the case of
combined treatment was reduced by pretreatment with
mecamylamine [F14min(1, 10) = 25.6499, p \ 0.05 for
ghrelin ? nicotine ? mecamylamine versus ghrelin ?
nicotine] or with GHRP-6 [F14min(1, 10) = 20.2275,
p \ 0.05 for ghrelin ? nicotine ? GHRP-6 versus ghre-
lin ? nicotine] (Fig. 3).
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Fig. 1 The effects of mecamylamine and GHRP-6 on the ghrelin-
induced dopamine release in rat amygdala. 1 lM ghrelin increased
significantly the fractional [3H]dopamine release from rat amygdala
slices following electrical stimulation. This effect was completely
reversed by 1 lM GHRP-6, and partially reversed by 100 lM
mecamylamine. Values are presented as mean percentages ± SEM
for each of the 2 min samples; the numbers in brackets indicate the
numbers of slices. Statistical analysis of the results was performed by
repeated measure analysis of variance (RMANOVA, Statistica v5.0,
StatSoft Inc.) followed by Tukey’s post hoc comparison test.
*p \ 0.05 ghrelin versus control; ##p \ 0.05 ghrelin ? mecamyl-
amine versus ghrelin alone; **p \ 0.05 ghrelin ? GHRP-6 versus
ghrelin alone
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Discussion
The present study demonstrates for the first time that
ghrelin stimulates locally the dopamine release in the rat
amygdala. This stimulation is mediated by GHS-R1A, as
GHR-P6 inhibited completely the ghrelin-induced amy-
gdalar dopamine release. There is a growing body of evi-
dence revealing that ghrelin plays a prominent role in
reward and reinforcement for both natural and artificial
rewards and addictive drugs, such as nicotine [14, 16, 19].
Previous studies suggested that this role is accomplished by
the activation of the cholinergic-dopaminergic reward link,
which encompasses the afferent cholinergic projection
from the LDTg to the VTA and the mesolimbic dopami-
nergic projection from the VTA to the NAcc [14–16]. Prior
experiments showed that local administration of ghrelin
into the LDTg or the VTA stimulates the dopamine release
from the nerve terminals of the mesencephalic dopami-
nergic neurons, such as the NAcc [16, 18, 30]. The increase
of accumbal dopamine release was reduced by different
nicotinic receptor antagonists [16, 31]. Our experiments
proved for the first time the direct action of ghrelin on the
amygdalar dopamine release. This process can be either
transmitted by presynaptic receptors or by cholinergic
interneurons, which is supported by the inhibitory activity
of selective nAchR antagonist. The amygdalar interaction
of ghrelin with GABA and glutamate cannot be excluded
either [22, 32]; this is suggested by the residual activity
observed in the presence of ghrelin and mecamylamine.
The present study correlates with previous ones, dem-
onstrating that nicotine stimulates the dopamine release in
the terminal fields of the mesencephalic dopaminergic
pathways, such as the ventral striatum (caudate-putamen),
the dorsal striatum (NAcc) and the amygdala [33–35]. The
stimulatory effect of nicotine is mediated by several nAchR
subtypes expressed on dopaminergic cell bodies (a4a5b2,
a4a6a5b2, a7) and on axon terminals (a4b2, a4a5b2,
a6b2b3, a4a6b2b3) [6]. The latter ones are localized in
these dopaminergic target areas, including the NAcc and
amygdala, which represent the principal relay stations in
the extended amygdala circuit [10, 12]. Along with the
cholinergic-dopaminergic reward link, the extended
amygdala circuit plays a prominent role in drug reward and
drug addiction [16, 36]. Besides the functional correlation,
there is a strong anatomical connection between these two
systems. On one hand, the NAcc is a common nucleus of
the two systems. On the other hand, the dopaminergic
neurons of the VTA innervate each nuclei of the extended
amygdala circuit (the NAcc, the BNST and the CeA) [10].
In addition, most of these nuclei express GHS-R1A and
nAchRs [6, 22, 37, 38] (Fig. 4). Mecamylamine blocked
the effect of nicotine, without a doubt, significantly, but
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Fig. 2 The effects of mecamylamine and GHRP-6 on the nicotine-
induced dopamine release in rat amygdala. 100 lM nicotine enhanced
significantly the fractional [3H]dopamine release from rat amygdala
slices following electrical stimulation. This effect was inhibited by
100 lM mecamylamine, but was not influenced by 1 lM GHRP-6.
Values are presented as mean percentages ± SEM for each of the
2 min samples; the numbers in brackets indicate the numbers of
slices. Statistical analysis of the results was performed by repeated
measure analysis of variance (RMANOVA, Statistica v5.0, StatSoft
Inc.) followed by Tukey’s post hoc comparison test. #p \ 0.05
nicotine versus control; ##p \ 0.05 nicotine ? mecamylamine versus
nicotine alone
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Fig. 3 The effects of mecamylamine and GHRP-6 on the co-
administered ghrelin and nicotine induced dopamine release in rat
amygdala. Combined treatment with 1 lM ghrelin and 100 lM
nicotine elevated significantly the fractional [3H]dopamine release
from rat amygdala slices following electrical stimulation. This effect
was reduced partially by pretreatment with both 100 lM mecamyl-
amine and 1 lM GHRP-6. Values are presented as mean percent-
ages ± SEM for each of the 2 min samples; the numbers in brackets
indicate the numbers of slices. Statistical analysis of the results was
performed by repeated measure analysis of variance (RMANOVA,
Statistica v5.0, StatSoft Inc.) followed by Tukey’s post hoc compar-
ison test. *p \ 0.05 ghrelin ? nicotine versus control; ##p \ 0.05
ghrelin ? nicotine ? mecamylamine versus ghrelin ? nicotine;
**p \ 0.05 ghrelin ? nicotine ? GHRP-6 versus ghrelin ? nicotine
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only partially. An explanation can be that other receptors,
such as NMDA receptors, may be involved in the amy-
gdalar action of nicotine, since nicotine increases NMDA
receptor-mediated excitatory postsynaptic currents in rat
CeA slices [38]. Another explanation can be that meca-
mylamine may also have a partial disinhibitory action on
the amygdalar dopamine as the activation of nAchRs
increases the frequency of GABAergic inhibitory post-
synaptic currents in the BLA [39].
Our experiments demonstrate that ghrelin and nicotine,
in single or co-administration, stimulate equally the dopa-
mine release in the amygdala, suggesting the role of both
ghrelin and nicotine in drug reward and drug addiction [16,
40, 41]. According to our results the final common pathway
should be the activation of cholinergic neurons since the
specific cholinergic antagonist was able to block both the
ghrelin- and the nicotine-induced dopamine response.
Through direct or indirect activation of the CeA and the
BLA ghrelin may increase the incentive value of motivated
behaviors, such as reward seeking [16]. However, the
intimate mechanism of rewarding action of ghrelin is yet to
be elucidated. Our results may have clinical implications.
Increased levels of ghrelin may increase the risk of
smoking in adolescent females [41]. Moreover, patients
with bulimia nervosa have elevated ghrelin levels and
higher prevalence for nicotine dependence [42, 43]. Taking
all these data into consideration, we share the opinion that
ghrelin signaling may serve as a novel pharmacological
target in the treatment of addictive disorders.
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